Navigation Links
Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:2/25/2008

CAMBRIDGE, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, announced today that three abstracts have been accepted for presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, April 23 - 27, 2008. Full abstracts can now be viewed at the EASL website at http://www.easl.ch.

David Standring, Ph.D., Executive Vice President, Biology at Idenix Pharmaceuticals, will present "In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors" in an oral presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.

Dr. Standring will also present, "Potent Antiviral Activity of Second Generation Nucleoside Inhibitors, IDX102 and IDX184, in HCV-Infected Chimpanzees" in an oral presentation session at 5:30 p.m. CET on Friday, April 25, 2008.

Erika Cretton-Scott, Ph.D., Director, Preclinical Pharmacology at Idenix Pharmaceuticals, will present "In Vitro Antiviral Activity and Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication" in a poster session beginning on Thursday, April 24, 2008.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Diseases and,Disorders, OLDSMAR, Fla., Jan. 29 ... ("Cryo-Cell" or the "Company"), one of the,largest ... today announced that,it has formalized a research ... ("Saneron") that represents an important milestone in,efforts ...
... RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial Limited and ... under which Merial will screen a Chimerix chemical library ... agreement, Merial has an,option to negotiate a license with ... "This collaboration with Chimerix provides us with an opportunity ...
... year end; no equity financings expected in 2008, ... continue in,2008; latest data for all programs to be ... Expansion of research and development investment in pharmacological, ... 2008, CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
Cached Biology Technology:Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 2Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 3Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 4Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/30/2014)... simple as inserting a medicated, disappearing fabric minutes before ... discovered a potentially faster way to deliver a topical ... spins the drug into silk-like fibers that quickly dissolve ... the drug than possible with other topical materials such ... a potentially more effective, discreet way to protect themselves ...
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3NexID Biometrics Joins the FIDO Alliance 2Across-the-board Impact Factor increases for Portland Press Limited 2
... enhance threat and radiation detection, improve life sciences ... received recognition for their innovation today. R&D Magazine ... Department of Energy,s Pacific Northwest National Laboratory with ... selects the 100 most innovative scientific and technological ...
... KINGSTON, R.I. July 8, 2010 A new ... been developed by a team of University of Rhode ... that can be triggered by non-invasive electromagnetic fields. ... Bose and graduate student Yanjing Chen was published in ...
... (July 8, 2010) By solving the three-dimensional structure ... group of McMaster University researchers have revealed new avenues ... living with hereditary colorectal cancers. The finding, published ... important step forward in the field of molecular and ...
Cached Biology News:PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 2PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 3PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 4PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 5Researchers develop drug delivery system using nanoparticles triggered by electromagnetic field 2DNA discovery opens new door to develop tools, therapies for hereditary cancers 2